Virtual cells built from 4D AI models and 'digital twins' could speed up drug discovery

Live updates

1. 5d ago

   Virtual Cells and AI Models Advance Drug Discovery

   Virtual cell models and digital twins are advancing drug discovery by simulating cellular states, predicting responses to genetic or pharmacological perturbations, and supporting hypothesis testing. Stanford's Virtual Biotech utilizes 37,000 AI agents to perform tasks such as target validation and clinical trials. Meanwhile, Illumina has launched the Billion Cell Atlas to identify drug targets and train artificial intelligence models. These systems biology frameworks integrate multimodal cellular data to model cell fate transitions and therapeutic responses, moving research from descriptive simulation toward perturbation-aware modeling.

   Why it matters

   Predicting cellular behavior has long been a central goal of systems biology to eradicate disease. Recent investments and frameworks, such as Biohub's Virtual Biology Initiative, aim to create predictive virtual cell models that evolve toward patient-specific digital twins. Researchers continue to face methodological challenges including noisy data, incomplete contextual information, limited causal inference, and fragmented benchmarking.

   What is confirmed

   • Virtual cells aim to provide computational representations of living cells that can simulate cellular states and predict responses to perturbations.
   • Stanford's Virtual Biotech employs 37,000 AI agents to perform tasks like target validation and clinical trials.
   • Illumina launched the Billion Cell Atlas to identify and validate drug targets and train artificial intelligence models.

   Still unconfirmed

   • Virtual cell research will eventually achieve patient-specific digital twins capable of comprehensive therapeutic predictions.

   What to watch next

   • Progress in resolving noisy data and incomplete contextual information in virtual cell modeling
   • Adoption and validation metrics for Illumina's Billion Cell Atlas in drug discovery
   • Performance outcomes from Stanford's 37,000 AI agents in clinical trial tasks
   Sources used for this update (4)

   1. www.oaepublish.com — Virtual cells: evolution, applications, and challenges
   2. scienceanddiscovery.com — Inside Stanford's Virtual Biotech: 37,000 AI Agents and the ...
   3. www.frontiersin.org — Frontiers | TwAIns: how artificial intelligence transforms ...
   4. pharmaphorum.com — JPM: Illumina launches 'unprecedented' disease biology atlas
   confidence 100%
2. 7d ago

   Virtual cells built from 4D AI models speed up drug discovery

   Researchers are using virtual cell models and 'digital twins' to accelerate drug discovery. Biohub's Virtual Biology Initiative, with $1.8 billion investment, aims to create predictive virtual cell models to eradicate disease. The initiative complements other AI-driven frameworks like Stanford's Virtual Biotech.

   Why it matters

   The use of virtual cell models and 'digital twins' has the potential to revolutionize the field of drug discovery. Current bottlenecks in AI modeling need to be overcome to achieve this goal. Better measurement tools are necessary to create accurate virtual cell models.

   What is confirmed

   • Biohub is investing $1.8 billion into a Virtual Biology Initiative.
   • The Virtual Biology Initiative aims to create predictive virtual cell models aimed at eradicating disease.
   • Better measurement tools are necessary to overcome current bottlenecks in AI modeling.

   What to watch next

   • Progress in AI-driven frameworks like Stanford's Virtual Biotech
   • Development of more accurate virtual cell models
   • Results from Biohub's Virtual Biology Initiative
   Sources used for this update (10)

   1. learn.microsoft.com — virtual (C++) | Microsoft Learn
   2. learn.microsoft.com — virtual keyword - C# reference | Microsoft Learn
   3. support.microsoft.com — Enable Virtualization on Windows | Microsoft Support
   4. support.microsoft.com — Use virtual card numbers to pay online | Microsoft Support
   5. learn.microsoft.com — how to install virtual machine - Microsoft Q&A
   6. learn.microsoft.com — Azure Virtual Desktop Hybrid Overview - Azure Virtual Desktop ...
   7. learn.microsoft.com — Virtualization documentation | Microsoft Learn
   8. learn.microsoft.com — Get started with virtual desktop architecture design
   9. learn.microsoft.com — Virtual Directory | Microsoft Learn
   10. learn.microsoft.com — What is Azure Virtual Desktop? - Azure - Azure Virtual Desktop...
   confidence 100%
3. 16d ago

   Biohub invests $1.8 billion to develop virtual cell models

   Biohub is investing $1.8 billion into a Virtual Biology Initiative to create predictive virtual cell models aimed at eradicating disease. Head of Science Alex Rives states that better measurement tools, such as transparent zebrafish imaging and the laser phase plate, are necessary to overcome current bottlenecks in AI modeling. Rives believes an information theoretic model of the cell is possible within five years. These efforts complement other AI-driven frameworks like Stanford's Virtual Biotech, which seeks to shorten drug discovery timelines.

   Why it matters

   Virtual cells and digital twins aim to replace slow, expensive physical tests with predictive simulations. This shift allows scientists to treat biology as programmable code. Previous efforts include the DESTINY project's use of routine tissue data to extract biological information.

   What is confirmed

   • Biohub's Virtual Biology Initiative is a 1.8 billion dollar push to create predictive virtual cell models and eradicate disease.
   • Alex Rives serves as the Head of Science at Biohub.

   Still unconfirmed

   • Measurement, rather than model architecture, is the primary bottleneck for AI cell modeling.

   What to watch next

   • Release of results from the Stanford Virtual Biotech platform
   • Development of the information theoretic cell model by 2031
   • Integration of Biohub measurement data into existing AI drug discovery frameworks
   Sources used for this update (5)

   1. agelessalpha.substack.com — WHEN BIOLOGY BECOMES PROGRAMMABLE: THE NEW FRONTIER OF HUMAN ...
   2. www.thefabulous.co — Biohub's $1.8B Virtual Biology Initiative Explained
   3. troy-technical.com — Virtual Biotech: AI-driven drug discovery framework and 2026 ...
   4. www.cognitiverevolution.ai — A World Model of Life: Biohub's Alex Rives on Virtual Cells ...
   5. www.ijpsjournal.com — Digital Twins In Drug Discovery, Development, And ...
   confidence 90%
4. 19d ago

   AI Agents and Digital Twins Target Faster Drug Discovery

   Researchers are deploying AI agents to emulate drug discovery organizations and digital twins to predict molecular data. The DESTINY project, funded by Innovate UK, uses a partnership between Queen Mary University of London, King's College London, and NHS Trusts Guy's and St Thomas and Barts Health to determine if AI can extract complex biological information from routine tissue data. This approach aims to replace expensive, time-consuming tests with predictive models to accelerate the development of new therapeutics.

   Why it matters

   These efforts build upon an existing 1.8 billion dollar collaboration involving Google DeepMind, Meta, and US government agencies. The broader goal is to integrate genetic and structural data to reduce screening timelines. This shift toward virtual cells seeks to bypass traditional laboratory bottlenecks.

   What is confirmed

   • The DESTINY project is a partnership between Queen Mary University of London, King's College London, Guy's and St Thomas, and Barts Health.
   • Innovate UK provided funding for PharosAI to investigate if AI can predict molecular information from routinely collected tissue data.

   Still unconfirmed

   • A platform using AI agents to emulate a human drug discovery organization could shave years off the discovery process.

   What to watch next

   • Validation results from the DESTINY project regarding the accuracy of AI-predicted molecular information.
   • Integration of PharosAI digital twins with the larger Biohub and DeepMind datasets.
   Sources used for this update (3)

   1. stanforddaily.com — AI-powered biotech could shave years off of drug discovery
   2. theelectricsheepreport.substack.com — AI Scientist Agents, Drug Discovery, Cell Biology & More ...
   3. www.bci.qmul.ac.uk — PharosAI awarded funding to explore AI ‘digital twins’ of ...
   confidence 80%
5. 22d ago

   Biohub Expands $1.8 Billion AI Virtual Cell Research Initiative

   An expanded $1.8 billion collaboration between Biohub, the Department of Energy, the National Institutes of Health, Google DeepMind, Isomorphic Labs, and Meta is constructing open biological datasets to drive predictive artificial intelligence models. This initiative runs alongside new intelligence software leveraging models like AlphaFold 3, along with specialized frameworks simulating brain cells to accelerate treatments for neurological conditions such as Alzheimer's disease. Combined models integrating structural, genetic, and chemical data are designed to reduce screening timelines while researchers continue to evaluate necessary validation standards for therapeutic discovery.

   Why it matters

   Traditional drug development suffers from lengthy screening timelines and high failure rates in identifying effective therapeutic targets. By utilizing predictive virtual cells and multimodal artificial intelligence models, researchers aim to simulate biological responses and cellular modifications digitally before conducting physical experiments. This computational approach bridges molecular genetics and chemical design to transform how treatments are discovered and tested.

   What is confirmed

   • Biohub has expanded a $1.8 billion collaboration involving the Department of Energy, the National Institutes of Health, Google DeepMind, Isomorphic Labs, and Meta.
   • The collaboration focuses on building open biological data to support predictive artificial intelligence models for disease research.

   Still unconfirmed

   • Simulating brain cells using AI agents in digital twins could lead to faster treatments for Alzheimer's and other brain diseases.
   • Combined structure, genetics, and chemistry models are successfully cutting screening time in drug discovery research.
   • Trial data shows how AI-powered drug discovery software works when building around models like AlphaFold 3.
   • Machine learning accelerates drug discovery across targets, molecule design, large language models, quantum computing, and Phase III trials.

   What to watch next

   • Publication of validation results for multimodal AI screening models
   • Progress reports on the $1.8 billion Biohub initiative datasets
   • Clinical trial data outcomes for software built around AlphaFold 3
   Sources used for this update (5)

   1. www.edtechinnovationhub.com — Biohub expands $1.8 billion virtual cell AI research effort ...
   2. theneuralfeed.com — New AI Simulates Brain Cells to Speed Up Drug Discovery
   3. aitechmodel.com — How Multimodal AI Is Speeding Up Drug Discovery Research
   4. octopi-digital.com — AI-Powered Drug Discovery Software: How It Works | Octopi Digital
   5. www.giroscience.com — AI Drug Discovery: How Machine Learning Works | Giroscience
   confidence 100%
6. 25d ago

   AI Virtual Cell Initiatives Advance Drug Discovery

   A global coalition involving the U.S. Department of Energy, the National Institutes of Health, Google DeepMind, Isomorphic Labs, Meta, NVIDIA, and Biohub is funding a $1.8 billion initiative to construct open biological datasets and predictive cellular models. This effort pairs with recent research published in Nature Biotechnology by Cambridge-based Shift Bioscience, which details a framework to evaluate deep learning genetic perturbation models. These artificial intelligence virtual cells forecast how cells react to genetic modifications to streamline therapeutic targeting. Meanwhile, reference definitions describe virtual entities as existing in essence or effect despite lacking actual physical form.

   Why it matters

   Predictive biological models and digital twins aim to revolutionize pharmaceutical research by simulating cellular responses before physical lab tests occur. The collaboration between major technology companies and government agencies highlights a growing push toward open-source biological simulation frameworks. Evaluating these models properly remains a core scientific challenge, addressed in part by new frameworks for testing deep learning predictions.

   What is confirmed

   • Cambridge-based Shift Bioscience published research in Nature Biotechnology detailing a framework for evaluating deep learning-based genetic perturbation models.
   • A global coalition including the U.S. Department of Energy, the National Institutes of Health, Google DeepMind, Isomorphic Labs, Meta, NVIDIA, and Biohub is funding a $1.8 billion initiative to build open biological datasets and predictive models.

   What to watch next

   • Further deployment of the $1.8 billion initiative by the global coalition
   • New findings from Shift Bioscience regarding deep learning genetic perturbation models
   Sources used for this update (2)

   1. www.yourdictionary.com — Virtual Definition & Meaning | YourDictionary
   2. tea.texas.gov — Virtual and Hybrid Education - Texas Education Agency
   confidence 100%
7. 27d ago

   Shift Bioscience Publishes Framework Supporting AI Virtual Cells

   Cambridge-based Shift Bioscience published new research in Nature Biotechnology detailing an improved framework for evaluating deep learning-based genetic perturbation models. These models function as AI virtual cells to predict cellular responses to genetic changes. This scientific advancement coincides with a $1.8 billion initiative funded by a global coalition, including the U.S. Department of Energy, the National Institutes of Health, Google DeepMind, Isomorphic Labs, Meta, and NVIDIA, alongside Biohub. The coalition aims to build open biological datasets and predictive models of cells and disease to accelerate drug discovery and therapeutic targeting.

   Why it matters

   Virtual cell technology shifts biotechnology toward digital simulation by utilizing 4D AI models to forecast complex cellular behavior. Backed by major government agencies and tech companies, this collaborative funding effort pushes biological research into large-scale computational screening. The integration of high-throughput laboratory screening with deep learning frameworks allows researchers to better identify drug targets.

   What is confirmed

   • Shift Bioscience published a study in Nature Biotechnology describing an improved framework for evaluating deep learning-based genetic perturbation models.
   • A coalition including the US Department of Energy, the National Institutes of Health, Google DeepMind, Isomorphic Labs, Meta, NVIDIA, and Biohub is backing a roughly $1.8 billion effort to build virtual cells and open biological datasets.

   Still unconfirmed

   • The distinction between new funding and existing commitments within the $1.8 billion virtual cell data effort remains partially unclear.

   What to watch next

   • Adoption rates of the Shift Bioscience evaluation framework across other biotechnology laboratories.
   • Further dataset releases and infrastructure milestones from the Biohub Virtual Biology Initiative coalition.
   Sources used for this update (6)

   1. today.ucsd.edu — News Archive - Biological Sciences
   2. interestingengineering.com — Google, Meta, and US build biology datasets for 'virtual cells'
   3. xab.info — Biotechnology Goes Digital: What We Know About the Unique ...
   4. bostonlifesciencestimes.com — Shift Bioscience Study Supports AI Virtual Cells for Drug ...
   5. www.metirai.com — Biohub's $1.8B Virtual Cell Push, Explained for AI Biology
   6. allsci.com — Biohub, DOE, NIH and AI giants launch USD 1.8 billion push to ...
   confidence 100%
8. 29d ago

   Biohub Secures $1.8B for Virtual Cell AI Models

   A global coalition has committed $1.8 billion to fund the Biohub Virtual Biology Initiative. Partners including the NIH, Google DeepMind, Isomorphic Labs, Meta, and the Department of Energy will generate open, AI-ready biological data. This initiative aims to build predictive models of cells and disease to forecast cellular behavior. While previous technical discussions centered on basic virtualization software and remote online service portals, this massive funding pushes virtual technology into advanced biomedical research. The new financial backing establishes a major collaborative effort to transform drug discovery through large-scale predictive cell modeling.

   Why it matters

   Past applications of virtual technology were limited to standard x86_64 virtualization platforms, DJ audio software, and online account management portals. The new multi-institution funding elevates virtual modeling into the biological sciences by uniting major tech companies and government agencies. Creating open data repositories allows researchers to construct complex AI systems capable of simulating human biology at the cellular level.

   What is confirmed

   • Biohub's Virtual Biology Initiative secured $1.8 billion to build artificial intelligence models that predict cell behavior.
   • Financial backers and partners for the initiative include DeepMind, Meta, the National Institutes of Health, Isomorphic Labs, and the Department of Energy.
   • The funding is dedicated to generating open, AI-ready biological data for building predictive models of cells and disease.

   What to watch next

   • Release of specific timelines for open data generation
   • Milestones in predictive cell model development from Biohub and its partners
   Sources used for this update (2)

   1. www.gadgetreview.com — DeepMind, Meta, and Isomorphic Labs Back Biohub’s $1.8B Virtual Cell Push
   2. Bioengineer.org — Global coalition commits $1.8 billion to build open data for AI models of biology
   confidence 100%
9. 31d ago

   Definitions and Tools Associated with Virtual Technologies

   Current discussions surrounding virtual technologies focus heavily on definitions found in major dictionaries alongside distinct software tools. Lexical definitions describe virtual items as things created by computer technology that appear to exist or exist in essence without physical actuality. Concurrently, software platforms utilize the term across different application domains. For instance, virtualization software targets x86_64 hardware with support for Windows and macOS platforms, while DJ applications provide real-time stem separation for live mixing. Additionally, online service portals utilize virtual designations to deliver remote account management and fund services to users around the clock.

   Why it matters

   The concept of virtual systems spans digital dictionaries, enterprise virtualization software, audio mixing applications, and remote public service portals. Understanding these diverse uses clarifies how computer-generated environments and platforms operate across distinct industries. While definitions emphasize computer-created existence, practical applications range from hardware emulation to audio manipulation and account services.

   What is confirmed

   • Virtual is defined in dictionaries as something created by computer technology that appears to exist or exists in essence but not in actuality.

   Still unconfirmed

   • VirtualBox version 7.1 offers support for macOS on Arm hardware and version 7.2 includes Windows on Arm support.
   • VirtualDJ 2026 introduces real-time stem separation on any track for live mashups and seamless transitions.

   What to watch next

   • Updates regarding virtual cell models and artificial intelligence drug discovery pipelines.
   • Further integration of virtualization software across new hardware platforms.
   Sources used for this update (8)

   1. www.virtualbox.org — Oracle VirtualBox
   2. virtualdj.com — VirtualDJ - Download VirtualDJ
   3. dictionary.cambridge.org — VIRTUAL | English meaning - Cambridge Dictionary
   4. www.pagibigfundservices.com — Virtual Pag-IBIG
   5. www.dictionary.com — VIRTUAL Definition & Meaning | Dictionary.com
   6. www.vocabulary.com — Virtual - Definition, Meaning & Synonyms | Vocabulary.com
   7. www.virtualbox.org — Downloads - Oracle VM VirtualBox
   8. dictionary.cambridge.org — VIRTUAL | definition in the Cambridge English Dictionary
   confidence 80%
10. 33d ago

    AI Virtual Cell Models Advance Drug Discovery and Proteomics

    Researchers are deploying new computational tools and massive datasets to construct virtual cell models that predict drug responses, resistance mechanisms, and patient outcomes. A team has built ProteinTalks, an artificial intelligence virtual cell model trained on more than 38 million time-resolved protein measurements from perturbed breast cancer cells. Additionally, a Baylor College of Medicine-led team combined protein analysis with artificial intelligence to accelerate the discovery of molecular glues designed to treat blood cancers and autoimmune diseases by neutralizing harmful proteins.

    Why it matters

    Preclinical drug discovery relies heavily on computational platforms, generative artificial intelligence, and virtual screening to prioritize chemical matter and target diseases. Recent developments merge massive proteomics datasets with structural modeling to help chemists optimize compounds before physical experiments. This work builds on industry efforts that leverage physics-based modeling and molecular simulation to assess ADMET properties and off-target liabilities.

    What is confirmed

    • Researchers built ProteinTalks, an AI virtual cell model trained on more than 38 million time-resolved protein measurements from perturbed breast cancer cells.
    • A Baylor College of Medicine-led team combined the analysis of thousands of proteins with artificial intelligence to accelerate the discovery of molecular glues.
    • The Baylor College of Medicine approach uncovered a new class of molecular glues to neutralize harmful proteins linked to blood cancers and autoimmune diseases.

    Still unconfirmed

    • OmniVCBench serves as a benchmark for evidence-grounded multimodal reasoning towards AI virtual cells.
    • New AI frameworks can read and rewrite cell trajectories inside living tissue.

    What to watch next

    • Further validation of AI-discovered molecular glues through physical experiments
    • Adoption and benchmarking results from OmniVCBench for multimodal reasoning in AI virtual cells
    Sources used for this update (4)

    1. scienmag.com — Massive Proteomics Dataset Powers a Virtual Cell Model for ...
    2. Phys.org — AI structure prediction speeds discovery of 'molecular glues ...
    3. arxiv.org — [2609.37773] OmniVCBench: Benchmarking Evidence-Grounded ...
    4. Bioengineer.org — New AI Framework Reads and Rewrites Cell Trajectories Inside ...
    confidence 90%
11. 35d ago

    Virtual Cells and AI Shape Preclinical Drug Discovery Programs

    Preclinical drug discovery expands as companies deploy computational tools, generative artificial intelligence, and virtual screening to target diseases and prioritize chemical matter. Biotechnology platforms combine disease intelligence with physics-based modeling and molecular simulation to guide design while predictive models assess ADMET properties and off-target liabilities. Meanwhile, industry competition centers on data control, with major firms like Recursion and NVIDIA holding financial stakes in the virtual cell race.

    Why it matters

    The integration of artificial intelligence into pharmaceutical development addresses high failure rates in early-stage research by simulating molecular interactions digitally. Companies offer integrated discovery programs where computational scientists, medicinal chemists, and biologists collaborate. Ownership of biological data remains a central point of competition among technology and pharmaceutical entities.

    What is confirmed

    • PozeSCAF operates as a preclinical contract research organization combining computational scientists, medicinal chemists, and biologists.
    • AxDrug uses disease and target intelligence, generative artificial intelligence, and virtual screening to identify and prioritize chemical matter.
    • Physics-based modeling and molecular simulation guide design while predictive models assess ADMET properties and potential off-target liabilities.
    • Recursion and NVIDIA are involved in the virtual cell development race, with NVIDIA maintaining a stake in the outcome.

    What to watch next

    • Commercial deployment data for AI-driven virtual cell models in clinical pipelines
    • Partnership announcements between major tech stakeholders and pharmaceutical contract research organizations
    Sources used for this update (3)

    1. pozescaf.com — PozeSCAF | AI-Powered Drug Discovery CRO & AxDrug ...
    2. rabbt.org — The Virtual Cell Race Isn't About Better Models. It's About ...
    3. www.ajmc.com — AI Poised to Reshape Drug Development: David Spigel, MD
    confidence 100%
12. 37d ago

    4D AI Models and Virtual Cells Accelerate Drug Discovery

    Researchers at the University of California, San Diego, and GenBio AI have engineered virtual cells using 4D AI models and physical digital twins to simulate how cellular components react to drug treatments. By tracking mitochondrial alterations across 40 thousand recordings, the tool successfully distinguished mechanisms of drug action with 75 percent accuracy. This technology aims to streamline pharmaceutical development by offering precise digital replicas of cellular behavior under various therapeutic conditions.

    Why it matters

    Artificial intelligence applications in biotechnology are shifting toward predictive modeling for safety, efficacy, and target identification. Digital twins can integrate multi-omics data to enable personalized simulations of cells and organs, opening new avenues for drug evaluation. However, the rapid evolution of these computational tools brings practical and regulatory challenges that researchers must resolve.

    What is confirmed

    • Researchers have created virtual cells that can predict and mimic mitochondrial changes associated with disease and drug responses.
    • Teams at the University of California and GenBio AI designed digital twins of human cells incorporating time as the fourth dimension.
    • The tool successfully distinguished mechanisms of drug action with 75 percent accuracy by tracking mitochondrial changes across 40 thousand recordings.

    Still unconfirmed

    • A research group at SciLifeLab focuses on building AI systems for cell and molecular biology.
    • Digital cells can predict which drugs will be most effective in deadly breast cancer.

    What to watch next

    • Resolution of practical and regulatory challenges facing digital twin applications in drug evaluation.
    • Further clinical validation of virtual cell models in specific oncology contexts like breast cancer.
    Sources used for this update (10)

    1. www.biotechniques.com — Accelerating Drug Discovery via Virtual Cells - BioTechniques
    2. www.archyde.com — AI 4D Imaging Model Predicts Cell Response to Drugs - Archyde
    3. aitimes.media — 4D AIモデルと「デジタルツイン」による仮想細胞が創薬を加速
    4. aicell.io — AICell Lab
    5. magazine.mindplex.ai — Other interesting news for 9.25.26 - magazine.mindplex.ai
    6. singularityhub.com — A Digital Cell Predicts Which Drugs Will Be Most Effective in ...
    7. www.generation-nt.com — Les chercheurs simulent désormais des cellules humaines en 4D ...
    8. biologyinsights.com — Artificial Intelligence in Drug Discovery: Current ...
    9. www.nature.com — The application, development and challenge of digital twin in ...
    10. www.clinicalleader.com — How Digital Twins Are Reshaping Clinical RD
    confidence 90%
13. 45d ago

    4D AI Virtual Cells Aim to Accelerate Drug Discovery

    Researchers are developing virtual cells using 4D AI models and digital twins to simulate how cells respond to drugs. These models aim to speed up the drug discovery process by creating digital replicas of cellular behavior. The UAE government and its embassy in the US have specifically highlighted the AIDO Cell AI model as a tool capable of simulating these cellular responses.

    Why it matters

    Traditional drug discovery often relies on slow, expensive physical trials. Digital twins allow scientists to test hypotheses in a virtual environment before moving to biological samples. This shift toward 4D modeling adds a temporal dimension to cellular simulations.

    What is confirmed

    • Virtual cells built from 4D AI models and digital twins may speed up drug discovery.
    • The AIDO Cell AI model can simulate cellular responses to drugs.

    What to watch next

    • Clinical trial data validating AIDO Cell predictions
    • Peer-reviewed performance metrics of 4D cellular models
    Sources used for this update (5)

    1. Phys.org — Virtual cells built from 4D AI models and 'digital twins' could speed up drug discovery
    2. Drug Discovery News — What is a virtual cell?
    3. thenationalnews.com — UAE hails AI cell model capable of simulating responses to drugs
    4. Labcompare — ‘Virtual Cells’ Speed Up Drug Discovery by Modeling Cells in 4D
    5. ua.news — UAE Embassy in the US highlights AIDO Cell AI model for simulating cellular responses to drugs
    confidence 90%